Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced Breast Cancer, Including Patients with Brain Metastases By Ogkologos - November 28, 2025 276 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HER2CLIMB-02 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Modest Effectiveness of Screening Colonoscopy for the Prevention of Colorectal Cancer... October 10, 2022 Texting May Help Reduce Disparities in Colorectal Cancer Screening March 19, 2021 Disguising Cancer as an Infection Helps the Immune System Eliminate Tumors July 22, 2022 Longer PFS in Patients with Advanced Melanoma Treated with TILs than... December 14, 2022 Load more HOT NEWS Girl Whose Insides Were Sucked From Her Body While Sitting On... Ovarian cancer screening trial did not save lives 10 Things Diet Soda Does to Your Body If You Drink... How Running and Training for a Marathon Helped Me Cope After...
